Conditions: Renal Cell Carcinoma
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 119
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the pharmacodynamic and biologic properties of BMS-936558 in subjects with metastatic renal cell carcinoma.

Detailed description:
Intervention Model: Parallel Dose Comparison

Arms:
arm 1: None arm 2: None arm 3: None arm 4: (treatment naive)

Interventions: intervention 1: BMS-936558 (Anti-PD-1) intervention 2: BMS-936558 (Anti-PD-1) intervention 3: BMS-936558 (Anti-PD-1)
Intervention descriptions: intervention 1: Solution, Intravenous infusion, 0.3 mg/kg, Every 3 weeks, Indefinitely depending on response intervention 2: Solution, Intravenous infusion, 2 mg/kg, Every 3 weeks, Indefinitely depending on response intervention 3: Solution, Intravenous infusion, 10 mg/kg, Every 3 weeks, Indefinitely depending on response

Protocol document: